Search - tctmd.com

Displaying 961 - 980 of 1583

Sort: Relevancy | Date

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

News Daily News

Ezetimibe With Statin Therapy: Biggest Bang in Higher-Risk ACS Patients

Michael O'Riordan

August 22, 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

August 22, 2019

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

News Daily News

New AHA Guidance on Omega-3 Fatty Acids for High Triglycerides

Michael O'Riordan

August 21, 2019

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

News Daily News

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

August 20, 2019

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

News Daily News

A Boost for Prescription Omega-3s? Not Yet: FDA Panel Set for November

Yael L. Maxwell

August 14, 2019

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

News Daily News

More Acute Stent Thrombosis With Synergy Stent in Bern PCI Registry

Michael O'Riordan

August 14, 2019

Statin Discontinuation in the Elderly Linked to More CV Events

News Daily News

Statin Discontinuation in the Elderly Linked to More CV Events

Yael L. Maxwell

August 01, 2019

Retrospective Study Links Testosterone Therapy to Lower Mortality After MI, but Controversy Continues

News Daily News

Retrospective Study Links Testosterone Therapy to Lower Mortality After MI, but Controversy Continues

Marcus A. Banks

July 31, 2019

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

News Daily News

CEC Identifies ‘Prognostically Important’ MIs: CHAMPION PHOENIX

Michael O'Riordan

July 30, 2019

Trial Points to Possible Benefit of Intensive BP-Lowering to Stave Off Recurrent Stroke

News Daily News

Trial Points to Possible Benefit of Intensive BP-Lowering to Stave Off Recurrent Stroke

July 29, 2019

RAS Inhibition Following TAVR

Presentation

RAS Inhibition Following TAVR

July 29, 2019

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

News Daily News

RAS Inhibition After TAVR Gains More Support, but RCT Still Needed

July 29, 2019

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

News Daily News

Baseline Ischemia Not Linked to 10-Year Events in Stable CAD: MASS II Analysis

July 23, 2019

Nonobstructive CAD on Cardiac CTA a Golden Opportunity to Boost Statin Prescribing

News Daily News

Nonobstructive CAD on Cardiac CTA a Golden Opportunity to Boost Statin Prescribing

Michael O'Riordan

July 22, 2019

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

News Daily News

Intensive Lipid-Lowering Slashes CVD in Elderly ACS Patients

Michael O'Riordan

July 19, 2019

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

News Conference News SCCT 2019

Time to Ease Up on Prior Authorization for PCSK9 Inhibitors?

Yael L. Maxwell

July 15, 2019

Imaging, Genes, Wearables: Some Predictions for the Future of Preventive Cardiology

News Conference News SCCT 2019

Imaging, Genes, Wearables: Some Predictions for the Future of Preventive Cardiology

Yael L. Maxwell

July 15, 2019

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

News Daily News

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

Marcus A. Banks

July 12, 2019

Clopidogrel-Aspirin in Minor Stroke/TIA of Maximum Benefit in First 21 Days

News Daily News

Clopidogrel-Aspirin in Minor Stroke/TIA of Maximum Benefit in First 21 Days

July 09, 2019

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

News Daily News

Most Supplements and Diets Don’t Lower CVD or Mortality Risks

Michael O'Riordan

July 09, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.